Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prostate cancer with oligometastatic relapse: stereotactic ablative radiotherapy plus durvalumab vs radiotherapy alone (randomized phase II)
2017-003827-31Phase 2Active
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jan 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in prostate cancer (PCa) (2 arms), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Progression-free survival at 2 years. Started Jan 2018; status: active.
02
Drugs
durvalumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-003827-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003827-31.